Neurology · Multiple System Atrophy
Teva's trial for TEV-56286 represents a significant opportunity to address a critical unmet need in the treatment of Multiple System Atrophy, a condition with few existing therapies. The outcome of this trial could not only enhance Teva's portfolio but also reshape competitive dynamics in the neurology space.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/21/2026, 6:31:10 AM
Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
Teva's trial for TEV-56286 represents a significant opportunity to address a critical unmet need in the treatment of Multiple System Atrophy, a condition with few existing therapies. The outcome of this trial could not only enhance Teva's portfolio but also reshape competitive dynamics in the neurology space. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).
Success in this trial could enhance Teva's portfolio in neurology and provide a new treatment option for MSA patients. The strongest clinical anchor is A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy (ClinicalTrials.gov), entity match (teva). In Neurology · Multiple System Atrophy, 2 regulatory and 1 competitive items passed relevance filtering for Teva.
The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial positions Teva in the competitive landscape for MSA treatments, an area with limited options.
Regulatory risk is concentrated around FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG) (FDA). Regulatory pathway relevance (nda). The trial's results will be pivotal for regulatory submissions and could influence the approval pathway for new treatments in this area.
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceA Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
ClinicalTrials.govhigh relevance
Entity match (teva)
FDA document
View sourceA Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
ClinicalTrials.govhigh relevance
Entity match (teva)
FDA document
View sourceA Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRoche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceBenefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceCost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceThe impact of (poly)phenol-rich sugarcane extract intervention on markers of gastrointestinal integrity and systemic inflammation in response to exertional-heat stress.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePotential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceDo subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisTeva's trial for TEV-56286 represents a significant opportunity to address a critical unmet need in the treatment of Multiple System Atrophy, a condition with few existing therapies. The outcome of this trial could not only enhance Teva's portfolio but also reshape competitive dynamics in the neurology space.
If successful, TEV-56286 could capture market share in a niche but underserved segment, potentially leading to substantial revenue growth for Teva.
The trial's results will be pivotal for regulatory submissions and could influence the approval pathway for new treatments in this area.
Monitor trial results and any announcements regarding efficacy and safety outcomes over the next 27 months.
Track for follow-up milestones; no immediate action required.